Dyadic at Lytham Partners: push from platform to sales

On Tuesday, September 29, 2026, Dyadic Applied BioSolutions (DYAI) addressed its shift from platform development to commercial execution during the Lytham Partners Fall 2026 Investor Conference. Management revealed the company now holds products in the market and multiple revenue streams, although they acknowledged that adoption will take time, and product launches can be uneven.

Dyadic moved beyond a licensing-and-grant model and now has commercially available products distributed through its own channels and partners. The life sciences sector is the primary focus in the near term, particularly cell culture media, molecular biology reagents, cell and gene therapy, diagnostics, and monoclonal antibodies.

Six products were highlighted on the market through Integrated BioTherapeutics, while commercial launches were introduced by Proliant Health & Biologicals, Inzymes, and Fermbox Bio. Two platforms, C1 and Dapibus, are employed to target different markets, from high-value biopharma proteins to lower-cost food and industrial proteins.

Dyadic's President and Chief Operating Officer, Joe Hazelton, explained that the company is now focused on sales, partnerships, and recurring revenue, having entered a new stage after years of platform work. The company's commercial push is supported by an industrial fungal gene expression platform developed over 30 years, utilized across life sciences, food nutrition, and bioindustrial applications.

Life sciences is the primary near-term revenue driver, with targets such as cell culture media, molecular biology reagents, cell and gene therapy, diagnostics, and monoclonal antibody production. Revert production can minimize contamination risks associated with animal- or plant-derived sources and enhance batch-to-batch consistency.

Dyadic emphasized that the business mix is changing, moving from licensing and grants to direct sales and partner-led commercialization. The company's stock (DYAI) closed at $0.477, up 2.36% in after-hours trading, with a market cap of $17.64 million and revenue of $3.8 million over the past year.